NEW YORK (GenomeWeb News) — Lipomics Technologies will use certain Agilent Technologies products under a research and diagnostic assay-development agreement, Lipomics said today.
 
Lipomics said it plans to develop biomarker-based assays focused on metabolic diseases caused by problems with lipid regulation.
 
Terms of the deal call for Agilent to contribute its 2100 Bioanalyzer and other products, including liquid and gas chromatographers, microarrays, and software as they are required, Lipomics said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.